Estudo randomizado | Decitabina em baixa dose vs. azacitidina em baixa dose nas síndromes mielodisplásicas de baixo risco.
12 Ago, 2022 | 17:58hLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Comentário no Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022